Baricitinib for Post-HSCT Persistent Thrombocytopenia
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorPeking University People's Hospital
About this trial
This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.
Eligibility criteria
Qualifiers
Aged 18-70 years;
Underwent allo-HSCT;
Meet the diagnostic criteria for delayed platelet engraftment (DPE) or secondary failure of platelet recovery (SFPR);
Have platelet counts consistently <20 ×10^9/L or transfusion-dependent within 14 days prior to enrollment;
Disqualifiers
Relapse of hematologic malignancy or MRD positivity;
Active infection;
Active graft-versus-host disease;
Thrombotic microangiopathy;
Trial design
Treatments tested in this trial
- Baricitinib
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov